Internal Medicine, Rheumatology · Greensboro, NC
NPI
1083860126
Since 2008
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1511 Westover Ter Ste 201
Greensboro, NC, 27408
Phone (336) 373-0611
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
88,840 services
Medicare patients, 2024
173
Average age 73
Drug cost, 2024
$3.1M
3,362 prescriptions
Company payments, 2025
$2,579
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Govinda Aryal was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 46,400 times for 17 patients. In total Govinda Aryal billed 88,840 services in 58 codes, and Medicare paid $1.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-02-01.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 46,400 | 17 | $3.20 | $149K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 7,277 | 11 | $33.77 | $246K |
| J0897 Injection, denosumab, 1 mg | Office | 1,860 | 20 | $20.59 | $38K |
| 99214 Office E&M - Established | Office | 362 | 149 | $83.28 | $30K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 297 | 40 | $0.51 | $151 |
| 96372 Injection Administration | Office | 244 | 36 | $10.11 | $2,466 |
| 96413 Chemotherapy Administration | Office | 196 | 29 | $91.28 | $18K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 170 | 96 | $11.59 | $1,971 |
| 96365 Intravenous Infusion, Hydration | Office | 104 | 19 | $45.42 | $4,724 |
| 96415 Chemotherapy Administration | Office | 97 | 12 | $19.73 | $1,914 |
| 73120 X-ray - Upper Extremity | Office | 56 | 28 | $21.43 | $1,200 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 38 | 24 | $0.74 | $28.25 |
| 73620 X-ray - Lower Extremity | Office | 38 | 19 | $19.78 | $751 |
| 73560 X-ray - Lower Extremity | Office | 28 | 14 | $23.19 | $649 |
| 99204 Office E&M - New | Office | 24 | 24 | $112.02 | $2,688 |
By year: 2022 $594K for 39,859 services; 2023 $690K for 49,524 services; 2024 $1.9M for 88,840 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 118 | 93 | $2.99 | $353 |
| 85025 Blood Count | 101 | 88 | $7.75 | $783 |
| 80053 Clinical Chemistry | 41 | 40 | $10.56 | $433 |
| 85651 Clinical Chemistry | 31 | 31 | $4.27 | $132 |
| 84550 Clinical Chemistry | 11 | 11 | $4.52 | $49.72 |
Medicare prescription drug claims, 2024
In 2024, the drug Govinda Aryal prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 633 prescriptions and refills. In total Govinda Aryal wrote 3,362 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 633 | 983 | 133 | $9,780 |
| Prednisone Generic | 542 | 756 | 184 | $3,268 |
| Hydroxychloroquine Sulfate Generic | 404 | 697 | 91 | $10K |
| Leflunomide Generic | 346 | 607 | 87 | $15K |
| Allopurinol Generic | 161 | 389 | 46 | $1,727 |
| Sulfasalazine Generic | 130 | 206 | 27 | $2,555 |
| Folic Acid Generic | 111 | 201 | 31 | $670 |
| Humira(Cf) Pen Adalimumab | 104 | 104 | 11 | $709K |
| Alendronate Sodium Generic | 93 | 233 | 27 | $794 |
| Orencia Clickject Abatacept | 48 | 48 | Under 11 | $274K |
| Enbrel Sureclick Etanercept | 42 | 42 | Under 11 | $315K |
| Azathioprine Generic | 39 | 77 | Under 11 | $1,411 |
| Colchicine Generic | 39 | 63 | 11 | $2,371 |
| Gabapentin Generic | 30 | 40 | Under 11 | $103 |
| Leucovorin Calcium Generic | 26 | 34 | Under 11 | $241 |
Brand drugs: - claims; generic drugs: 2,781 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Govinda Aryal $2,579 ($2,579 in general payments such as food, travel and fees) from 17 companies. The largest payer was Amgen Inc. with $471.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 37 | $471 |
| Abbvie Inc. ABBV | 17 | $382 |
| UCB, Inc. UCB.BR | 20 | $352 |
| Mallinckrodt Hospital Products Inc. | 15 | $285 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $237 |
| Janssen Biotech, Inc. JNJ | 8 | $167 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $132 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $112 |
| Pfizer Inc. PFE | 5 | $102 |
| GlaxoSmithKline, LLC. GSK | 6 | $90.62 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.